{"gene":"DSG2","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1994,"finding":"DSG2 was identified as the ubiquitous desmoglein isoform present in all desmosome-containing tissues (epithelia, myocardium, lymph node follicles), encoding a 1069 amino acid transmembrane glycoprotein that functions as a Ca2+-dependent cell adhesion molecule and component of the desmosomal cadherin complex.","method":"cDNA cloning, amino acid sequence analysis, Northern blot, tissue expression profiling","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1 — original cloning and characterization with comprehensive expression profiling across tissues; foundational paper with 216 citations","pmids":["8143788"],"is_preprint":false},{"year":1996,"finding":"DSG2 protein localizes to desmosomes in all desmosome-containing tissues including stratified and simple epithelia, myocardium, and lymph node follicles; in stratified squamous epithelia, DSG2 is restricted to the basal cell layer. Antibodies to extracellular domains react with half-desmosomes on surfaces of uncoupled epithelial cells, demonstrating its role in cell-cell coupling.","method":"Immunocytochemistry with monoclonal and polyclonal antibodies targeting extracellular and cytoplasmic domains","journal":"Differentiation; research in biological diversity","confidence":"High","confidence_rationale":"Tier 2 — direct subcellular localization by multiple antibodies in multiple tissues, replicated across labs","pmids":["8641550"],"is_preprint":false},{"year":1995,"finding":"The fourth armadillo repeat of plakoglobin is required for its high-affinity binding to the cytoplasmic domain of DSG2; bacterially expressed 12-repeat plakoglobin (lacking the fourth repeat) binds DSG2 with lower affinity than the 13-repeat form, establishing DSG2 as a direct binding partner of plakoglobin at desmosomes.","method":"In vitro binding assay with bacterially expressed proteins, deletion mutant analysis","journal":"Journal of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro binding with mutagenesis (deletion of specific armadillo repeat)","pmids":["8749329"],"is_preprint":false},{"year":2007,"finding":"Suprabasal overexpression of DSG2 in transgenic mouse epidermis causes keratinocyte hyperproliferation, apoptosis resistance, and skin tumor susceptibility through activation of multiple signaling pathways including PI3K/AKT, MEK-MAPK, STAT3, and NF-κB, with enhanced EGF receptor activation required for anchorage-independent survival.","method":"Transgenic mouse model (involucrin-promoter Dsg2), ex vivo keratinocyte culture, pathway inhibitor studies, chemical carcinogenesis assay","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 — transgenic gain-of-function in vivo with multiple pathway readouts and pharmacological validation; 102 citations","pmids":["17284515"],"is_preprint":false},{"year":2009,"finding":"The DSG2-N266S mutation acts in a dominant-negative, dose-dependent manner to cause arrhythmogenic right ventricular cardiomyopathy (ARVC) in transgenic mice; myocyte necrosis is the key initiating event, triggering inflammatory response, calcification, fibrous tissue replacement, and myocardial atrophy.","method":"Cardiac-specific transgenic mouse overexpressing mutant dsg2 (N271S), multiple transgene expression levels, histopathology, electrophysiology","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — dose-dependent dominant-negative effect shown across multiple transgenic lines with mechanistic histopathological analysis; 167 citations","pmids":["19635863"],"is_preprint":false},{"year":2016,"finding":"DSG2 activates EGFR signaling through a c-Src and Caveolin-1 (Cav1)-dependent mechanism via lipid rafts: DSG2 overexpression recruits to and displaces Cav1, EGFR, and c-Src from light-density lipid raft fractions, leading to c-Src and EGFR activation, increased cell proliferation and migration. DSG2 knockdown abrogates EGFR, c-Src, and STAT3 activation in response to EGF.","method":"Sucrose density fractionation, STED imaging, siRNA knockdown, overexpression in SCC cells, proliferation and migration assays, lipid raft perturbation (MβCD)","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (fractionation, super-resolution imaging, KD/OE, pharmacological perturbation) in single study","pmids":["26918609"],"is_preprint":false},{"year":2017,"finding":"ARVC-associated DSG2 mutations (studied by single-molecule force spectroscopy) significantly alter the kinetics and thermodynamics of homophilic DSG2 dimerization without directly affecting the binding motif; the free energy landscape of DSG2 dimerization reveals a high activation barrier consistent with a strand-swapping binding motif, and mutations reduce cell-cell adhesion in a dispase-based assay.","method":"Single-molecule force spectroscopy, Jarzynski's equality for thermodynamic analysis, dispase-based cell dissociation assay with HT1080 cells overexpressing WT and mutant Dsg2","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1 — single-molecule biophysics combined with cellular adhesion assay; rigorous thermodynamic characterization of binding mechanism","pmids":["29062102"],"is_preprint":false},{"year":2018,"finding":"DSG2 directly interacts with EGFR and undergoes heterotypic binding events on the surface of living enterocytes via its extracellular domain; DSG2 is required for EGFR localization at intercellular junctions and for Src-mediated EGFR activation; Src binds EGFR and is required for co-localization of EGFR and DSG2 at cell-cell contacts. DSG2-deficient enterocytes show impaired barrier properties and increased proliferation.","method":"Atomic force microscopy on living cells, Co-IP, siRNA knockdown, EGFR localization imaging, barrier function assays","journal":"Cellular and molecular life sciences","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding shown by AFM on live cells plus Co-IP; loss-of-function with defined cellular phenotype","pmids":["29980799"],"is_preprint":false},{"year":2018,"finding":"DSG2 regulates self-renewal and pluripotency of human pluripotent stem cells predominantly through β-catenin/Slug-mediated epithelial-to-mesenchymal transition (EMT); DSG2 depletion markedly decreased hPSC proliferation, pluripotency marker expression, and embryonic body and teratoma formation.","method":"Monoclonal antibody-based identification, siRNA knockdown, flow cytometry, embryoid body and teratoma assays, Western blot for β-catenin/Slug pathway","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined molecular pathway (β-catenin/Slug/EMT) but mechanistic link relies on downstream pathway analysis without direct DSG2-β-catenin interaction assay","pmids":["29910125"],"is_preprint":false},{"year":2019,"finding":"ARVC-associated DSG2 mutations alter the N-glycosylation pattern of desmoglein-2; wildtype and mutant DSG2 display different glycosylation patterns despite mutations not directly affecting N-glycosylation consensus sequences, indicating complex molecular interactions between DSG2 mutations and N-glycosylations.","method":"De-glycosylation assays, lectin blot analysis, genetic inhibition of glycosylation","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal biochemical methods in single study; single lab","pmids":["30885746"],"is_preprint":false},{"year":2020,"finding":"DSG2 undergoes heterophilic interactions with DSG3; immunoprecipitation and cell-free atomic force microscopy demonstrated Dsg2-Dsg3 heterophilic binding with comparable frequency, strength, Ca2+-dependency, and catch-bond behavior to homophilic interactions, but with longer lifetime. Heterophilic Dsg2-Dsg3 interactions are significantly less inhibited by pemphigus vulgaris autoantibodies compared to homophilic Dsg3 interactions.","method":"Co-immunoprecipitation, cell-free atomic force microscopy, Dsg3-deficient keratinocyte model, pemphigus skin ex vivo model","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1-2 — cell-free AFM plus Co-IP provides direct biophysical and biochemical evidence of heterophilic interaction with functional consequence","pmids":["33193387"],"is_preprint":false},{"year":2020,"finding":"DSG2 knockdown in anaplastic thyroid cancer cells increased cell migration and invasion through the c-Met/Src/Rac1 signaling axis without altering EMT markers; specific c-Met inhibition blocked motility of shDsg2-depleted cells, and decreased membrane DSG2 increased metastatic potential in vivo.","method":"shRNA knockdown, migration/invasion assays, in vivo metastasis model, pharmacological c-Met inhibition, Western blot for signaling intermediates","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined pathway placement (c-Met/Src/Rac1) and in vivo validation","pmids":["33022637"],"is_preprint":false},{"year":2021,"finding":"A DSG2 truncation mutation (p.S363X) localized in the extracellular domain results in absence of the truncated protein at the plasma membrane, as shown by in vitro transfection experiments, supporting loss-of-function through failure of membrane trafficking.","method":"In vitro cell transfection, immunofluorescence localization of truncated vs. wildtype DSG2","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment with functional implication; single lab, single method","pmids":["34202524"],"is_preprint":false},{"year":2022,"finding":"Cardiac-specific knockout of Dsg2 causes myocardial lipid accumulation and cardiac dysfunction through impaired fatty acid β-oxidation resulting from declined mTOR-4EBP1-PPARα signaling; rapamycin worsened while mTOR/4EBP1 overexpression or PPARα reactivation (fenofibrate/AAV9-Pparα) rescued the phenotype.","method":"Cardiac-specific Dsg2 knockout mouse, echocardiography, lipid staining, Western blot, AAV-mediated gene delivery, rapamycin treatment, pharmacological PPARα activation","journal":"Acta pharmaceutica Sinica. B","confidence":"High","confidence_rationale":"Tier 2 — cardiac-specific KO with multiple orthogonal rescue experiments defining the mTOR-4EBP1-PPARα pathway","pmids":["36815030"],"is_preprint":false},{"year":2022,"finding":"Dsg2 deficiency causes cardiac fibrosis via PPARα deficiency and hyperactivation of STAT3 and SMAD3; Dsg2 gene silencing in HL-1 cells upregulates fibrotic markers (α-SMA, Collagen I); STAT3 siRNA inhibits fibrotic marker expression; PPARα activation by fenofibrate or AAV9-Pparα reduces fibrosis and decreases phosphorylation of STAT3, SMAD3, and AKT.","method":"CS-Dsg2-/- mouse, Masson staining, Western blot, qPCR, siRNA knockdown in HL-1 cells, AAV gene delivery","journal":"Cells","confidence":"High","confidence_rationale":"Tier 2 — KO model with siRNA epistasis and multiple rescue experiments defining PPARα-STAT3-SMAD3 pathway","pmids":["36291052"],"is_preprint":false},{"year":2022,"finding":"TROP2 interacts with DSG2 in gastric cancer cells (identified by co-immunoprecipitation and mass spectrometry); TROP2 overexpression reduces DSG2 levels and desmosome adhesion, promoting cell invasion and migration through EGFR/AKT and DSG2/plakoglobin/β-catenin pathways.","method":"Co-immunoprecipitation, mass spectrometry, TROP2 overexpression/knockdown, electron microscopy of desmosome assembly, Western blot for pathway analysis","journal":"Current cancer drug targets","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP/MS for interaction plus functional pathway analysis; single lab","pmids":["35392784"],"is_preprint":false},{"year":2024,"finding":"PRKD2 (serine/threonine-protein kinase D2) phosphorylates DSG2 at threonine 730 (T730); this phosphorylation promotes esophageal squamous cell carcinoma cell migration and invasion by activating EGFR, Src, AKT, and ERK signaling pathways; DSG2-T730 phosphorylation-deficient mutants abolish the pro-migratory effect.","method":"Interactome analysis, phosphorylation assay, site-directed mutagenesis (T730), migration/invasion assays, Western blot for signaling pathways","journal":"The Journal of pathology","confidence":"High","confidence_rationale":"Tier 1 — identification of kinase-substrate relationship with mutagenesis of phosphorylation site and functional validation","pmids":["38411280"],"is_preprint":false},{"year":2024,"finding":"DSG2 F531C mutation causes protein misfolding recognized by BiP within the endoplasmic reticulum, triggering ER stress and activating PERK-ATF4 signaling; elevated ATF4 increases TGF-β1 expression in cardiomyocytes, which activates cardiac fibroblasts via paracrine signaling to promote cardiac fibrosis; PERK-ATF4 inhibition attenuated fibrosis in knock-in mice.","method":"Dsg2 F536C knock-in mice (CRISPR/Cas9), transcriptomic analysis, mass spectrometry, Co-IP with BiP, neonatal/adult cardiomyocytes isolation, PERK inhibitor treatment, histopathology","journal":"BMC medicine","confidence":"High","confidence_rationale":"Tier 1-2 — knock-in model with mechanistic pathway dissection using Co-IP, transcriptomics, MS, and pharmacological rescue","pmids":["39227800"],"is_preprint":false},{"year":2024,"finding":"DSG2 ectodomain organization (measured by fluorescence polarization) gradually increases over 8 hours during desmosome assembly and correlates with increasing adhesive strength; in wound healing, ectodomain order increases in assembling desmosomes at the leading edge of migratory cells.","method":"Fluorescence polarization microscopy, scratch wound assay, time-lapse imaging","journal":"Cell adhesion & migration","confidence":"Medium","confidence_rationale":"Tier 2 — direct structural measurement during assembly with functional correlation; single lab","pmids":["38566311"],"is_preprint":false},{"year":2025,"finding":"DSG2 is identified as a dominant counter receptor of Siglec-9 in melanoma cells via proximity labeling and CRISPR knockout screening; the DSG2-Siglec-9 interaction is mainly dependent on sialic acid-bearing N-glycans on DSG2; blocking this interaction significantly enhances macrophage phagocytosis of melanoma cells.","method":"Proximity labeling, CRISPR knockout screening, binding assays, macrophage phagocytosis assay, glycan dependency analysis","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 — two orthogonal discovery methods (proximity labeling + CRISPR screen) with mechanistic follow-up showing glycan dependency and functional phagocytosis readout","pmids":["39813162"],"is_preprint":false},{"year":2024,"finding":"DSG2 interacts with c-MYC (by co-immunoprecipitation) in cervical cancer cells; DSG2 overexpression combined with c-MYC inhibition significantly decreases cell proliferation, migration, and ADAM17 expression compared to DSG2 overexpression alone, placing DSG2 upstream of c-MYC/ADAM17 in a proliferation/migration pathway.","method":"Co-immunoprecipitation, c-MYC inhibitor treatment, qPCR, Western blot, CCK-8 and Transwell assays","journal":"Cancer management and research","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP for interaction with functional epistasis; single lab","pmids":["38948682"],"is_preprint":false},{"year":2025,"finding":"DSG2 deficiency in cardiomyocytes results in Z-disc structural defects and increased myosin detachment rate; Ca2+-activated force is markedly reduced in DSG2-mutant permeabilized left ventricular cardiac muscle bundles but preserved in isolated permeabilized cardiomyocytes, revealing that DSG2 is required for force transmission between sarcomeres (tissue-level mechanotransduction) in addition to cell-cell mechanical coupling.","method":"Homozygous Dsg2 knock-in mice (adolescent and adult), permeabilized cardiac muscle bundles vs. isolated cardiomyocyte force measurements, X-ray diffraction, echocardiography","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 — rigorous mechanical measurements distinguishing tissue vs. cell levels; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.10.03.680335"],"is_preprint":true},{"year":2025,"finding":"Proximity labeling and quantitative mass spectrometry identified over 300 proteins in the DSG2 interactome in neonatal cardiomyocytes; unique DSG2-associated proteins include connexin 43 (gap junction protein) and plakin family cytolinker proteins; plakoglobin (JUP) and plakophilin 2 (PKP2) are the most abundant proteins shared between DSG2 and N-cadherin interactomes.","method":"Proximity labeling (BioID), quantitative mass spectrometry, comparison with N-cadherin interactome","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — systematic proximity labeling MS identifies interactome; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.06.09.658637"],"is_preprint":true},{"year":2025,"finding":"P-cadherin (Pcad) facilitates desmosome assembly by directly interacting with DSG2 on opposing cells via heterophilic strand-swap dimerization involving conserved tryptophan residues; stiffening the hinge on the swapped β-strands reduces heterophilic dimer formation; introduction of strand-swap competent Pcad into cells lacking classical cadherins rescues desmosome assembly.","method":"Single-molecule atomic force microscopy, super-resolution and confocal imaging, site-directed mutagenesis of strand-swap residues, atomistic simulations, cell-based desmosome assembly assay","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1 — single-molecule biophysics plus mutagenesis plus cell rescue assay; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.09.15.676363"],"is_preprint":true},{"year":2025,"finding":"Pathogenic autoantibodies from ACM patients bind DSG2 in hiPSC-CMs, cleave DSG2, and reduce DSG2 interaction at the molecular level; these autoantibodies impair cardiomyocyte cohesion by activating GSK-3β upstream of p38MAPK, leading to phosphorylation and junctional loss of β-catenin; GSK-3β inhibition rescues the loss of cell cohesion induced by ACM autoantibodies.","method":"hiPSC-cardiomyocytes from ACM patients, IgG fractionation, dispase dissociation assay, GSK-3β inhibition, Western blot for p38MAPK/β-catenin phosphorylation","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway dissection with pharmacological rescue; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2025.06.25.661311"],"is_preprint":true},{"year":2025,"finding":"Oxymatrine (OMT) directly binds DSG2 (confirmed by CETSA, DARTS, and microscale thermophoresis) and stabilizes it; OMT and its metabolite matrine reduce DSG2 cleavage by inhibiting caspase-8 activity, thereby enhancing intestinal epithelial barrier function; knockdown of DSG2 abolishes the protective effects of OMT.","method":"CETSA, DARTS, microscale thermophoresis, caspase-8 activity assay, lentiviral DSG2 knockdown, Caco-2 and FD duodenal spheroid models","journal":"Phytomedicine","confidence":"High","confidence_rationale":"Tier 1-2 — three orthogonal direct binding methods plus mechanistic follow-up showing caspase-8 cleavage and KD rescue","pmids":["41076918"],"is_preprint":false},{"year":2025,"finding":"DSG2 mediates conversion between desmosome and adherens junctions in circulating tumor cell (CTC) clusters; high DSG2 expression maintains desmosome-dominant intercellular junctions in CTC clusters; HIF-1α positively controls DSG2-mediated desmosome junctions; inhibiting HIF-1α promotes conversion from desmosome to adherens junctions, destabilizing CTC clusters.","method":"CTC cluster analysis, junction protein characterization by IF, HIF-1α inhibition, in vivo metastasis models","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined pathway (HIF-1α→DSG2→desmosome junction type) and in vivo validation; single lab","pmids":["41381723"],"is_preprint":false},{"year":2010,"finding":"Ectopic suprabasal expression of DSG2 in transgenic mice reduces epidermal blister formation in response to pemphigus foliaceus antibodies and exfoliative toxins (ETA); DSG2 overexpression enhances retention of DSG1 at cell-cell borders, demonstrating DSG2's direct role in cell adhesion and protection of desmosomal components.","method":"Transgenic mouse model (involucrin-Dsg2), injection of ETA and PF IgG, immunofluorescence for Dsg1 localization","journal":"Dermatology research and practice","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function transgenic model with defined adhesion phenotype; single lab","pmids":["20631906"],"is_preprint":false},{"year":2006,"finding":"UV radiation induces DSG2 downregulation in human lens epithelial cells via EGFR activation, Rac2 translocation, and NADPH oxidase-mediated generation of reactive oxygen species (ROS); this pathway is analogous to that activated by H2O2 treatment.","method":"Cell culture, UV irradiation, ROS measurement, EGFR activation assay, Rac2/NADPH oxidase activity, Western blot for DSG2","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — defined molecular pathway (EGFR→Rac2/NADPH oxidase→ROS→DSG2 downregulation) with pharmacological/genetic dissection; single lab","pmids":["16820949"],"is_preprint":false},{"year":2015,"finding":"DSG2 regulates cystatin A (CSTA) expression in keratinocytes; knockdown of DSG2 reduces CSTA expression; conversely, CSTA knockdown causes cytoplasmic mislocalization of DSG2, perturbs cytokeratin 14, reduces desmoplakin levels, and induces loss of cell adhesion. Combined knockdown of DSG2 and CSTA has a synergistic effect on loss of adhesion, demonstrating crosstalk between DSG2 and CSTA in regulating cell-cell adhesion.","method":"siRNA/shRNA knockdown, microarray, qPCR, immunoblotting, immunohistochemistry, dispase-based adhesion assay, mechanical stretching","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal knockdown experiments with defined adhesion phenotype and localization readout; single lab","pmids":["25785582"],"is_preprint":false},{"year":2018,"finding":"DSG2 overexpression in basal keratinocytes accelerates full-thickness wound closure and increases wound-adjacent keratinocyte proliferation; DSG2 induces increased release and proteolytic processing of urokinase-type plasminogen activator receptor (uPAR), and wounding further enhances uPAR and laminin-332 in transgenic epidermis.","method":"Transgenic mice (keratin14-Dsg2), wound healing assay, antibody profiler secretome array, immunohistochemistry","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic gain-of-function with defined wound healing phenotype and secretome analysis linking mechanism to uPAR; single lab","pmids":["29753032"],"is_preprint":false}],"current_model":"DSG2 is a transmembrane desmosomal cadherin that mediates Ca2+-dependent homophilic and heterophilic (DSG3, P-cadherin) cell-cell adhesion via strand-swap dimerization of its extracellular domain; intracellularly it binds plakoglobin (requiring the fourth armadillo repeat) and associates with connexin 43 and plakin cytolinkers in cardiomyocytes; at the plasma membrane DSG2 organizes lipid raft signaling platforms to activate EGFR via c-Src/Cav1-dependent transactivation, stimulating PI3K/AKT, MEK-MAPK, STAT3, and NF-κB pathways that drive proliferation, survival, and migration; PRKD2 phosphorylates DSG2 at T730 to further potentiate EGFR/Src/AKT/ERK signaling; in cardiomyocytes, DSG2 loss disrupts intercalated disc integrity, impairs force transmission between sarcomeres, and through ER stress-PERK-ATF4-TGF-β1 and mTOR-PPARα axes drives the fibrofatty remodeling characteristic of arrhythmogenic cardiomyopathy; sialylated N-glycans on DSG2 enable it to act as a 'don't eat me' signal by engaging Siglec-9 on macrophages, and the extracellular domain serves as a functional receptor for group B human adenoviruses."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing DSG2 as the ubiquitous desmosomal cadherin resolved the question of which desmoglein isoform is present across all desmosome-bearing tissues, providing the foundation for all subsequent functional studies.","evidence":"cDNA cloning, sequence analysis, and Northern blot across multiple tissues","pmids":["8143788"],"confidence":"High","gaps":["No functional assay of adhesion performed","Protein-level expression not quantified across tissues"]},{"year":1996,"claim":"Demonstration that DSG2 localizes to desmosomes and half-desmosomes on uncoupled cell surfaces established its direct participation in cell-cell coupling rather than merely being a desmosome-associated protein.","evidence":"Immunocytochemistry with multiple antibodies in stratified/simple epithelia and myocardium","pmids":["8641550"],"confidence":"High","gaps":["No dynamic assembly or turnover measurement","Localization in non-epithelial cell types incompletely mapped"]},{"year":1995,"claim":"Identification of the plakoglobin–DSG2 interaction via armadillo repeat 4 defined the first direct cytoplasmic binding partner, explaining how DSG2 couples to the desmosomal plaque.","evidence":"In vitro binding assay with bacterially expressed deletion mutants of plakoglobin","pmids":["8749329"],"confidence":"High","gaps":["No in vivo validation of armadillo repeat 4 requirement","Other cytoplasmic partners not addressed"]},{"year":2007,"claim":"Transgenic DSG2 overexpression in mouse epidermis revealed that DSG2 is not merely a structural adhesion molecule but an activator of PI3K/AKT, MEK-MAPK, STAT3, and NF-κB signaling via EGFR, explaining how desmosomal cadherins influence proliferation and tumor susceptibility.","evidence":"Involucrin-Dsg2 transgenic mice with pathway inhibitor studies and chemical carcinogenesis","pmids":["17284515"],"confidence":"High","gaps":["Direct DSG2–EGFR interaction mechanism not resolved","Signaling model based on overexpression, not endogenous levels"]},{"year":2009,"claim":"The Dsg2-N266S transgenic mouse demonstrated that ARVC-associated DSG2 mutations act in a dominant-negative manner, with myocyte necrosis as the initiating event preceding fibrofatty replacement — establishing the disease mechanism in vivo.","evidence":"Cardiac-specific transgenic mouse with graded expression levels, histopathology, electrophysiology","pmids":["19635863"],"confidence":"High","gaps":["Whether necrosis versus apoptosis predominates remained debated","Downstream molecular pathways from DSG2 loss to necrosis not defined"]},{"year":2016,"claim":"Mechanistic dissection of DSG2-EGFR crosstalk showed that DSG2 organizes lipid raft platforms and displaces Caveolin-1, enabling c-Src-dependent EGFR transactivation — explaining the signaling effects observed in transgenic mice.","evidence":"Sucrose density fractionation, STED imaging, siRNA knockdown, MβCD perturbation in SCC cells","pmids":["26918609"],"confidence":"High","gaps":["Direct physical DSG2–EGFR binding not demonstrated at this stage","Mechanism of Cav1 displacement unclear"]},{"year":2017,"claim":"Single-molecule force spectroscopy revealed that DSG2 homophilic dimerization follows strand-swap mechanics with a high activation barrier, and that ARVC mutations alter binding kinetics without disrupting the binding motif — providing a biophysical explanation for how mutations weaken adhesion.","evidence":"Single-molecule AFM force spectroscopy with Jarzynski analysis plus dispase assay in HT1080 cells","pmids":["29062102"],"confidence":"High","gaps":["Structural basis of kinetic changes not resolved at atomic level","In vivo relevance of altered kinetics not tested"]},{"year":2018,"claim":"Direct DSG2–EGFR interaction on living enterocyte surfaces was confirmed by AFM, and DSG2 was shown to be required for EGFR junctional localization via Src, closing the gap between lipid raft models and direct receptor engagement.","evidence":"AFM on living cells, Co-IP, siRNA knockdown in enterocytes with barrier function readout","pmids":["29980799"],"confidence":"High","gaps":["Binding interface between DSG2 and EGFR ectodomains not mapped","Whether interaction is direct or adaptor-mediated at atomic resolution unknown"]},{"year":2020,"claim":"Discovery of heterophilic DSG2–DSG3 binding with catch-bond behavior and longer lifetime than homophilic interactions expanded the adhesion model beyond homodimerization and explained partial resistance to pemphigus autoantibodies.","evidence":"Cell-free AFM and Co-IP with Dsg3-deficient keratinocytes and pemphigus skin ex vivo model","pmids":["33193387"],"confidence":"High","gaps":["Structural basis of heterophilic versus homophilic preference not determined","In vivo significance of heterophilic binding in intact desmosomes not tested"]},{"year":2022,"claim":"Cardiac-specific Dsg2 knockout revealed that DSG2 loss causes lipid accumulation and cardiac dysfunction through impaired mTOR–4EBP1–PPARα signaling and parallel STAT3/SMAD3-driven fibrosis, providing the first metabolic explanation for arrhythmogenic cardiomyopathy pathogenesis downstream of desmosome disruption.","evidence":"Cardiac-specific Dsg2 KO mice with rapamycin worsening, AAV-PPARα rescue, fenofibrate treatment, siRNA epistasis in HL-1 cells","pmids":["36815030","36291052"],"confidence":"High","gaps":["How DSG2 loss signals to mTOR not defined","Whether metabolic dysfunction is primary or secondary to structural defects unclear"]},{"year":2024,"claim":"Identification of PRKD2 as the kinase phosphorylating DSG2 at T730 established the first site-specific post-translational modification that potentiates DSG2-EGFR/Src/AKT/ERK signaling, linking kinase signaling directly to desmosomal cadherin function in cancer cell migration.","evidence":"Interactome analysis, phosphorylation assay, T730A mutagenesis, migration/invasion assays in ESCC cells","pmids":["38411280"],"confidence":"High","gaps":["Whether T730 phosphorylation occurs in normal tissues unknown","Phosphatase responsible for dephosphorylation not identified"]},{"year":2024,"claim":"The Dsg2-F531C knock-in mouse showed that ARVC mutations can trigger ER stress through BiP recognition of misfolded DSG2, activating PERK–ATF4–TGF-β1 paracrine signaling from cardiomyocytes to fibroblasts — providing a proteostasis-based fibrosis mechanism distinct from the mTOR/PPARα axis.","evidence":"CRISPR knock-in mice, Co-IP with BiP, transcriptomics, MS, PERK inhibitor rescue","pmids":["39227800"],"confidence":"High","gaps":["Whether ER stress pathway is universal across all ARVC-associated DSG2 mutations not tested","Relative contribution of ER stress versus metabolic pathways to disease unclear"]},{"year":2025,"claim":"Identification of DSG2 as the dominant Siglec-9 counter-receptor on melanoma cells, dependent on sialylated N-glycans, revealed a glyco-immune checkpoint function for DSG2 as a 'don't eat me' signal — expanding its role beyond adhesion into immune evasion.","evidence":"Proximity labeling, CRISPR KO screening, glycan dependency analysis, macrophage phagocytosis assay","pmids":["39813162"],"confidence":"High","gaps":["Whether DSG2–Siglec-9 interaction occurs in non-melanoma contexts unknown","In vivo therapeutic significance of blocking this axis not yet established"]},{"year":null,"claim":"Key unresolved questions include the atomic-resolution structure of DSG2 in complex with EGFR and Siglec-9, the mechanism by which DSG2 loss activates mTOR suppression in cardiomyocytes, and whether the ER stress and metabolic pathways represent parallel or convergent disease mechanisms in arrhythmogenic cardiomyopathy.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal/cryo-EM structure of DSG2 ectodomain complexes with non-cadherin partners","Mechanism linking DSG2 loss to mTOR inactivation undefined","Relative contributions of ER stress versus metabolic versus mechanical defects to ARVC progression unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1,6,10,23]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,5,7]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,5,7,12]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,7,16]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,6,10,27]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,13,14,17]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[19]}],"complexes":["desmosome","intercalated disc"],"partners":["JUP","EGFR","DSG3","PKP2","PRKD2","GJA1","TROP2","SIGLEC9"],"other_free_text":[]},"mechanistic_narrative":"DSG2 is a ubiquitously expressed desmosomal cadherin that mediates Ca²⁺-dependent cell-cell adhesion through homophilic and heterophilic strand-swap dimerization and couples intercellular junctions to intracellular signaling networks controlling proliferation, survival, and tissue integrity. Its extracellular domain engages in homophilic binding with high activation-barrier kinetics consistent with strand-swapping, forms heterophilic dimers with DSG3 and P-cadherin, and carries sialylated N-glycans that engage macrophage Siglec-9 to suppress phagocytosis [PMID:29062102, PMID:33193387, PMID:39813162]. Intracellularly, DSG2 binds plakoglobin (via armadillo repeat 4), organizes lipid raft signaling platforms to activate EGFR through c-Src/Caveolin-1-dependent transactivation driving PI3K/AKT, MEK-MAPK, STAT3, and NF-κB cascades, and is phosphorylated by PRKD2 at T730 to potentiate EGFR/Src/AKT/ERK signaling [PMID:8749329, PMID:26918609, PMID:38411280]. Loss-of-function and dominant-negative DSG2 mutations cause arrhythmogenic cardiomyopathy through myocyte necrosis, ER stress–PERK–ATF4–TGF-β1-driven fibrosis, and impaired mTOR–PPARα-dependent fatty acid oxidation, establishing DSG2 as a causal gene for this disease [PMID:19635863, PMID:39227800, PMID:36815030]."},"prefetch_data":{"uniprot":{"accession":"Q14126","full_name":"Desmoglein-2","aliases":["Cadherin family member 5","HDGC"],"length_aa":1118,"mass_kda":122.3,"function":"A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion (PubMed:17559062, PubMed:38395410). Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion. Required for proliferation and viability of embryonic stem cells in the blastocyst, thereby crucial for progression of post-implantation embryonic development (By similarity). Maintains pluripotency by regulating epithelial to mesenchymal transition/mesenchymal to epithelial transition (EMT/MET) via interacting with and sequestering CTNNB1 to sites of cell-cell contact, thereby reducing translocation of CTNNB1 to the nucleus and subsequent transcription of CTNNB1/TCF-target genes (PubMed:29910125). Promotes pluripotency and the multi-lineage differentiation potential of hematopoietic stem cells (PubMed:27338829). Plays a role in endothelial cell sprouting and elongation via mediating the junctional-association of cortical actin fibers and CDH5 (PubMed:27338829). Promotes cardiomyocyte cell homeostasis and desmosome junction formation at intercalated disks, as a result plays a role in the maintenance of cardiac conduction and heart chamber integrity (By similarity). Positively regulates pancreatic islet development and maintenance of endothelial cell barrier integrity in the pancreas, therefore involved in the controlled release of insulin from islet cells into the circulation in response to glucose (By similarity). Plays a role in limiting inflammatory infiltration and the apoptotic response to injury in kidney tubular epithelial cells, potentially via its role in maintaining cell-cell adhesion and the epithelial barrier (PubMed:38395410). Acts as a positive modulator of CSK and EGFR activation via sequestering them away from lipid rafts, this is independent of its role in desmosome cell junctions (PubMed:26918609). Also disrupts the localization of CAV1 to lipid rafts resulting in its distribution throughout the cytoplasm (PubMed:26918609)","subcellular_location":"Cell membrane; Cell junction, desmosome; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q14126/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DSG2","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"DDOST","stoichiometry":0.2},{"gene":"KRTCAP2","stoichiometry":0.2},{"gene":"OST4","stoichiometry":0.2},{"gene":"RPN1","stoichiometry":0.2},{"gene":"RPN2","stoichiometry":0.2},{"gene":"STT3B","stoichiometry":0.2},{"gene":"VAMP3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/DSG2","total_profiled":1310},"omim":[{"mim_id":"615821","title":"CARDIOMYOPATHY, DILATED, WITH WOOLLY HAIR, KERATODERMA, AND TOOTH AGENESIS; DCWHKTA","url":"https://www.omim.org/entry/615821"},{"mim_id":"612877","title":"CARDIOMYOPATHY, DILATED, 1BB; CMD1BB","url":"https://www.omim.org/entry/612877"},{"mim_id":"610476","title":"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; ARVD11","url":"https://www.omim.org/entry/610476"},{"mim_id":"610193","title":"ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; ARVD10","url":"https://www.omim.org/entry/610193"},{"mim_id":"607892","title":"DESMOGLEIN 4; DSG4","url":"https://www.omim.org/entry/607892"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cell Junctions","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":99.0},{"tissue":"parathyroid gland","ntpm":148.5}],"url":"https://www.proteinatlas.org/search/DSG2"},"hgnc":{"alias_symbol":["CDHF5"],"prev_symbol":[]},"alphafold":{"accession":"Q14126","domains":[{"cath_id":"2.60.40.60","chopping":"57-151","consensus_level":"high","plddt":92.0917,"start":57,"end":151},{"cath_id":"2.60.40.60","chopping":"159-264","consensus_level":"medium","plddt":95.1269,"start":159,"end":264},{"cath_id":"2.60.40.60","chopping":"272-381","consensus_level":"medium","plddt":94.8678,"start":272,"end":381},{"cath_id":"2.60.40.60","chopping":"387-491","consensus_level":"high","plddt":93.827,"start":387,"end":491},{"cath_id":"2.60.40.60","chopping":"499-597","consensus_level":"high","plddt":90.161,"start":499,"end":597}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14126","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14126-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14126-F1-predicted_aligned_error_v6.png","plddt_mean":64.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DSG2","jax_strain_url":"https://www.jax.org/strain/search?query=DSG2"},"sequence":{"accession":"Q14126","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14126.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14126/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14126"}},"corpus_meta":[{"pmid":"8143788","id":"PMC_8143788","title":"Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins.","date":"1994","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/8143788","citation_count":216,"is_preprint":false},{"pmid":"16773573","id":"PMC_16773573","title":"DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy.","date":"2006","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16773573","citation_count":188,"is_preprint":false},{"pmid":"19635863","id":"PMC_19635863","title":"Myocyte necrosis underlies progressive myocardial dystrophy in mouse dsg2-related arrhythmogenic right ventricular cardiomyopathy.","date":"2009","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19635863","citation_count":167,"is_preprint":false},{"pmid":"17284515","id":"PMC_17284515","title":"Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17284515","citation_count":102,"is_preprint":false},{"pmid":"19458482","id":"PMC_19458482","title":"Increased expression of Dsg2 in malignant skin carcinomas: A tissue-microarray based study.","date":"2009","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/19458482","citation_count":89,"is_preprint":false},{"pmid":"8641550","id":"PMC_8641550","title":"Immunological identification and characterization of the desmosomal cadherin Dsg2 in coupled and uncoupled epithelial cells and in human tissues.","date":"1996","source":"Differentiation; research in biological diversity","url":"https://pubmed.ncbi.nlm.nih.gov/8641550","citation_count":85,"is_preprint":false},{"pmid":"26918609","id":"PMC_26918609","title":"c-Src/Cav1-dependent activation of the EGFR by Dsg2.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26918609","citation_count":53,"is_preprint":false},{"pmid":"22457526","id":"PMC_22457526","title":"A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses.","date":"2012","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/22457526","citation_count":52,"is_preprint":false},{"pmid":"8749329","id":"PMC_8749329","title":"The fourth armadillo repeat of plakoglobin (gamma-catenin) is required for its high affinity binding to the cytoplasmic domains of E-cadherin and desmosomal cadherin Dsg2, and the tumor suppressor APC protein.","date":"1995","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8749329","citation_count":49,"is_preprint":false},{"pmid":"30454721","id":"PMC_30454721","title":"A founder homozygous DSG2 variant in East Asia results in ARVC with full penetrance and heart failure phenotype.","date":"2018","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30454721","citation_count":45,"is_preprint":false},{"pmid":"1612610","id":"PMC_1612610","title":"The human gene (DSG2) coding for HDGC, a second member of the desmoglein subfamily of the desmosomal cadherins, is, like DSG1 coding for desmoglein DGI, assigned to chromosome 18.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1612610","citation_count":40,"is_preprint":false},{"pmid":"16820949","id":"PMC_16820949","title":"UV radiation down-regulates Dsg-2 via Rac/NADPH oxidase-mediated generation of ROS in human lens epithelial cells.","date":"2006","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16820949","citation_count":33,"is_preprint":false},{"pmid":"25785582","id":"PMC_25785582","title":"Cell cycle- and cancer-associated gene networks activated by Dsg2: evidence of cystatin A deregulation and a potential role in cell-cell adhesion.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25785582","citation_count":29,"is_preprint":false},{"pmid":"29980799","id":"PMC_29980799","title":"Dsg2 via Src-mediated transactivation shapes EGFR signaling towards cell adhesion.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/29980799","citation_count":28,"is_preprint":false},{"pmid":"28578331","id":"PMC_28578331","title":"Whole Genome Sequence Identified a Rare Homozygous Pathogenic Mutation of the DSG2 Gene in a Familial Arrhythmogenic Cardiomyopathy Involving Both Ventricles.","date":"2017","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28578331","citation_count":25,"is_preprint":false},{"pmid":"29062102","id":"PMC_29062102","title":"Arrhythmogenic cardiomyopathy related DSG2 mutations affect desmosomal cadherin binding kinetics.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29062102","citation_count":24,"is_preprint":false},{"pmid":"29910125","id":"PMC_29910125","title":"DSG2 Is a Functional Cell Surface Marker for Identification and Isolation of Human Pluripotent Stem Cells.","date":"2018","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29910125","citation_count":24,"is_preprint":false},{"pmid":"33917638","id":"PMC_33917638","title":"Hemi- and Homozygous Loss-of-Function Mutations in DSG2 (Desmoglein-2) Cause Recessive Arrhythmogenic Cardiomyopathy with an Early Onset.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33917638","citation_count":23,"is_preprint":false},{"pmid":"30885746","id":"PMC_30885746","title":"In vitro analysis of arrhythmogenic cardiomyopathy associated desmoglein-2 (DSG2) mutations reveals diverse glycosylation patterns.","date":"2019","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30885746","citation_count":19,"is_preprint":false},{"pmid":"28818065","id":"PMC_28818065","title":"Case reports of two pedigrees with recessive arrhythmogenic right ventricular cardiomyopathy associated with homozygous Thr335Ala variant in DSG2.","date":"2017","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28818065","citation_count":19,"is_preprint":false},{"pmid":"36815030","id":"PMC_36815030","title":"Reactivation of PPARα alleviates myocardial lipid accumulation and cardiac dysfunction by improving fatty acid β-oxidation in Dsg2-deficient arrhythmogenic cardiomyopathy.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36815030","citation_count":18,"is_preprint":false},{"pmid":"31220685","id":"PMC_31220685","title":"A common indel polymorphism of the Desmoglein-2 (DSG2) is associated with sudden cardiac death in Chinese populations.","date":"2019","source":"Forensic science international","url":"https://pubmed.ncbi.nlm.nih.gov/31220685","citation_count":17,"is_preprint":false},{"pmid":"33193387","id":"PMC_33193387","title":"Dsg2 Upregulation as a Rescue Mechanism in Pemphigus.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33193387","citation_count":16,"is_preprint":false},{"pmid":"36291052","id":"PMC_36291052","title":"Activation of PPARα Ameliorates Cardiac Fibrosis in Dsg2-Deficient Arrhythmogenic Cardiomyopathy.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36291052","citation_count":15,"is_preprint":false},{"pmid":"20631906","id":"PMC_20631906","title":"Superficial dsg2 expression limits epidermal blister formation mediated by pemphigus foliaceus antibodies and exfoliative toxins.","date":"2010","source":"Dermatology research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/20631906","citation_count":15,"is_preprint":false},{"pmid":"35392784","id":"PMC_35392784","title":"TROP2 Down-regulated DSG2 to Promote Gastric Cancer Cell Invasion and Migration by EGFR/AKT and DSG2/PG/β-Catenin Pathways.","date":"2022","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/35392784","citation_count":15,"is_preprint":false},{"pmid":"34224109","id":"PMC_34224109","title":"Desmoglein 2 (DSG2) Is A Receptor of Human Adenovirus Type 55 Causing Adult Severe Community-Acquired Pneumonia.","date":"2021","source":"Virologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/34224109","citation_count":14,"is_preprint":false},{"pmid":"40123482","id":"PMC_40123482","title":"Natural History and Clinical Outcomes of Patients With DSG2/DSC2 Variant-Related Arrhythmogenic Right Ventricular Cardiomyopathy.","date":"2025","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/40123482","citation_count":13,"is_preprint":false},{"pmid":"33022637","id":"PMC_33022637","title":"Dsg2-mediated c-Met activation in anaplastic thyroid cancer motility and invasion.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33022637","citation_count":13,"is_preprint":false},{"pmid":"29753032","id":"PMC_29753032","title":"Enhancement of Cutaneous Wound Healing by Dsg2 Augmentation of uPAR Secretion.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29753032","citation_count":12,"is_preprint":false},{"pmid":"34202524","id":"PMC_34202524","title":"The Double Mutation DSG2-p.S363X and TBX20-p.D278X Is Associated with Left Ventricular Non-Compaction Cardiomyopathy: Case Report.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34202524","citation_count":12,"is_preprint":false},{"pmid":"30716529","id":"PMC_30716529","title":"Sudden death in mild hypertrophic cardiomyopathy with compound DSG2/DSC2/MYH6 mutations: Revisiting phenotype after genetic assessment in a master runner athlete.","date":"2019","source":"Journal of electrocardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30716529","citation_count":12,"is_preprint":false},{"pmid":"37696084","id":"PMC_37696084","title":"Molecular insight into arrhythmogenic cardiomyopathy caused by DSG2 mutations.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37696084","citation_count":11,"is_preprint":false},{"pmid":"39227800","id":"PMC_39227800","title":"Hyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant.","date":"2024","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39227800","citation_count":11,"is_preprint":false},{"pmid":"36375513","id":"PMC_36375513","title":"Up-regulation of Dsg2 confered stem cells with malignancy through wnt/β-catenin signaling pathway.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36375513","citation_count":11,"is_preprint":false},{"pmid":"32827795","id":"PMC_32827795","title":"Selective elimination of human pluripotent stem cells by Anti-Dsg2 antibody-doxorubicin conjugates.","date":"2020","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/32827795","citation_count":10,"is_preprint":false},{"pmid":"30177324","id":"PMC_30177324","title":"Compound and heterozygous mutations of DSG2 identified by Whole Exome Sequencing in arrhythmogenic right ventricular cardiomyopathy/dysplasia with ventricular tachycardia.","date":"2018","source":"Journal of electrocardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30177324","citation_count":9,"is_preprint":false},{"pmid":"30129429","id":"PMC_30129429","title":"Case report of familial sudden cardiac death caused by a DSG2 p.F531C mutation as genetic background when carrying with heterozygous KCNE5 p.D92E/E93X mutation.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30129429","citation_count":8,"is_preprint":false},{"pmid":"36016457","id":"PMC_36016457","title":"Properties of Adenovirus Vectors with Increased Affinity to DSG2 and the Potential Benefits of Oncolytic Approaches and Gene Therapy.","date":"2022","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/36016457","citation_count":8,"is_preprint":false},{"pmid":"25660657","id":"PMC_25660657","title":"Arrhythmogenic right ventricular cardiomyopathy with left ventricular involvement: a novel splice site mutation in the DSG2 gene.","date":"2015","source":"Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25660657","citation_count":8,"is_preprint":false},{"pmid":"31653443","id":"PMC_31653443","title":"Distal myopathy induced arrhythmogenic right ventricular cardiomyopathy in a pedigree carrying novel DSG2 null variant.","date":"2019","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/31653443","citation_count":7,"is_preprint":false},{"pmid":"38411280","id":"PMC_38411280","title":"Serine/threonine-protein kinase D2-mediated phosphorylation of DSG2 threonine 730 promotes esophageal squamous cell carcinoma progression.","date":"2024","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/38411280","citation_count":7,"is_preprint":false},{"pmid":"35521959","id":"PMC_35521959","title":"Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma.","date":"2022","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/35521959","citation_count":6,"is_preprint":false},{"pmid":"38566311","id":"PMC_38566311","title":"Dsg2 ectodomain organization increases throughout desmosome assembly.","date":"2024","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/38566311","citation_count":6,"is_preprint":false},{"pmid":"31645976","id":"PMC_31645976","title":"Two pedigrees with arrhythmogenic right ventricular cardiomyopathy linked with R49H and F531C mutation in DSG2.","date":"2019","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/31645976","citation_count":6,"is_preprint":false},{"pmid":"37288269","id":"PMC_37288269","title":"Misdiagnosed myocarditis in arrhythmogenic cardiomyopathy induced by a homozygous variant of DSG2: a case report.","date":"2023","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37288269","citation_count":5,"is_preprint":false},{"pmid":"39813162","id":"PMC_39813162","title":"Proximity Labeling and Genetic Screening Reveal that DSG2 is a Counter Receptor of Siglec-9 and Suppresses Macrophage Phagocytosis.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/39813162","citation_count":5,"is_preprint":false},{"pmid":"39597880","id":"PMC_39597880","title":"Prevalence and Correlates of Anti-DSG2 Antibodies in Arrhythmogenic Right Ventricular Cardiomyopathy and Myocarditis: Immunological Insights from a Multicenter Study.","date":"2024","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39597880","citation_count":4,"is_preprint":false},{"pmid":"30391969","id":"PMC_30391969","title":"PKP2 and DSG2 genetic variations in Latvian arrhythmogenic right ventricular dysplasia/cardiomyopathy registry patients.","date":"2018","source":"Anatolian journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/30391969","citation_count":3,"is_preprint":false},{"pmid":"38948682","id":"PMC_38948682","title":"DSG2 and c-MYC Interact to Regulate the Expression of ADAM17 and Promote the Development of Cervical Cancer.","date":"2024","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/38948682","citation_count":3,"is_preprint":false},{"pmid":"40615400","id":"PMC_40615400","title":"DSG2 promotes pancreatic cancer stem cell maintenance via support of tumour and macrophage cellular cross-talk.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/40615400","citation_count":2,"is_preprint":false},{"pmid":"34438094","id":"PMC_34438094","title":"Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34438094","citation_count":2,"is_preprint":false},{"pmid":"34012299","id":"PMC_34012299","title":"Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Probably Caused by DSG2 p.Val149Ile Mutation as Genetic Background When Carrying with Heterozygous PRRT2 p.Arg217ProfsTer8 Mutation: A Case Report.","date":"2021","source":"International medical case reports journal","url":"https://pubmed.ncbi.nlm.nih.gov/34012299","citation_count":2,"is_preprint":false},{"pmid":"40316058","id":"PMC_40316058","title":"DSG2 attenuates gemcitabine efficacy through PTX3 in lung adenocarcinoma.","date":"2025","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/40316058","citation_count":2,"is_preprint":false},{"pmid":"33640690","id":"PMC_33640690","title":"CRISPR/Cas9-edited PKP2 knock-out (JMUi001-A-2) and DSG2 knock-out (JMUi001-A-3) iPSC lines as an isogenic human model system for arrhythmogenic cardiomyopathy (ACM).","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33640690","citation_count":2,"is_preprint":false},{"pmid":"39706847","id":"PMC_39706847","title":"Four cardiomyopathy patients with a heterozygous DSG2 p.Arg119Ter variant.","date":"2024","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/39706847","citation_count":1,"is_preprint":false},{"pmid":"33974263","id":"PMC_33974263","title":"[Analysis of DSG2, TTN and GATA4 gene variants in patients with Brugada syndrome from Henan].","date":"2021","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33974263","citation_count":1,"is_preprint":false},{"pmid":"40956261","id":"PMC_40956261","title":"Inflammatory Features in Homozygous DSG2 Cardiomyopathy Mimicking Cardiac Sarcoidosis.","date":"2025","source":"JACC. Case reports","url":"https://pubmed.ncbi.nlm.nih.gov/40956261","citation_count":1,"is_preprint":false},{"pmid":"37921471","id":"PMC_37921471","title":"Toward the understanding of DSG2 and CD46 interaction with HAdV-11 fiber, a super-complex analysis.","date":"2023","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/37921471","citation_count":1,"is_preprint":false},{"pmid":"40887256","id":"PMC_40887256","title":"Biventricular Dysfunction in Knock-in Mice With Dsg2 Variants Specific for Japanese Arrhythmogenic Right Ventricular Cardiomyopathy.","date":"2025","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/40887256","citation_count":1,"is_preprint":false},{"pmid":"40115818","id":"PMC_40115818","title":"Case report: Severe arrhythmogenic cardiomyopathy in a young girl with compound heterozygous DSG2 and MYBPC3 variants with a 6-year follow-up.","date":"2025","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40115818","citation_count":1,"is_preprint":false},{"pmid":"39253717","id":"PMC_39253717","title":"Case report: Additional variants induced sudden cardiac death among pediatric ACM with DSG2 homozygous mutant genotype: a report of three cases.","date":"2024","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39253717","citation_count":1,"is_preprint":false},{"pmid":"31292664","id":"PMC_31292664","title":"Correction to: Dsg2 via Src-mediated transactivation shapes EGFR signaling towards cell adhesion.","date":"2019","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/31292664","citation_count":1,"is_preprint":false},{"pmid":"36210707","id":"PMC_36210707","title":"[Silencing CD46 and DSG2 in host A549 cells inhibits entry of human adenovirus type 3 and type 7 and reduces interleukin-8 release].","date":"2022","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/36210707","citation_count":1,"is_preprint":false},{"pmid":"38375917","id":"PMC_38375917","title":"Ser194Leu DSG2 mutation, associated with arrhythmogenic left ventricular cardiomyopathy and ventricular tachycardia.","date":"2024","source":"Pacing and clinical electrophysiology : PACE","url":"https://pubmed.ncbi.nlm.nih.gov/38375917","citation_count":0,"is_preprint":false},{"pmid":"41076918","id":"PMC_41076918","title":"Oxymatrine ameliorates ulcerative colitis via improving epithelial barrier function through targeting DSG2.","date":"2025","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41076918","citation_count":0,"is_preprint":false},{"pmid":"41691490","id":"PMC_41691490","title":"DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.","date":"2026","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41691490","citation_count":0,"is_preprint":false},{"pmid":"41381723","id":"PMC_41381723","title":"Hirudin suppresses hematogenous metastasis by targeting desmosome junction transition in circulating tumor cell clusters via HIF-1α-DSG2 signaling.","date":"2025","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41381723","citation_count":0,"is_preprint":false},{"pmid":"41989164","id":"PMC_41989164","title":"CD46 and DSG2 synergistically mediate human adenovirus type 7 infection.","date":"2026","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/41989164","citation_count":0,"is_preprint":false},{"pmid":"41679545","id":"PMC_41679545","title":"Desmoglein 2 (DSG2)-knockout human respiratory epithelial cell model to study species B adenovirus receptor usage.","date":"2026","source":"Virologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/41679545","citation_count":0,"is_preprint":false},{"pmid":"41727586","id":"PMC_41727586","title":"DSG2-Directed CAR-T Cells Safely and Universally Eliminate Solid Tumors.","date":"2026","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/41727586","citation_count":0,"is_preprint":false},{"pmid":"41350507","id":"PMC_41350507","title":"The oncogenic role of lncRNA DSG2-AS1 and its functional link to SGK1 in laryngeal squamous cell carcinoma.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41350507","citation_count":0,"is_preprint":false},{"pmid":"40019607","id":"PMC_40019607","title":"SFRP4 Knockdown Attenuates Dsg2-Deficient Arrhythmogenic Cardiomyopathy by Down-Regulating TGF-β and Smad3.","date":"2025","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40019607","citation_count":0,"is_preprint":false},{"pmid":"41531208","id":"PMC_41531208","title":"TROP2 Promotes Tumor Cell Migration through Downregulation of DSG2 Revealed by Super-Resolution Fluorescence Imaging.","date":"2026","source":"Analytical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/41531208","citation_count":0,"is_preprint":false},{"pmid":"40106965","id":"PMC_40106965","title":"Generation of the human iPSC line UNIPDi006-A from a patient with arrhythmogenic cardiomyopathy carrying the DSG2 c.1672C > T pathogenic variant.","date":"2025","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/40106965","citation_count":0,"is_preprint":false},{"pmid":"41980193","id":"PMC_41980193","title":"Targeting PPAR-γ Reduces Fibrosis and Arrhythmogenic Remodeling in DSG2-Linked Arrhythmogenic Cardiomyopathy.","date":"2026","source":"Circulation. Genomic and precision medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41980193","citation_count":0,"is_preprint":false},{"pmid":"41158880","id":"PMC_41158880","title":"Right Atrial Myxoma in a Young Patient with a DSG-2 Genetic Mutation: A Case Report.","date":"2025","source":"Case reports in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41158880","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.03.680335","title":"Desmoglein-2 deficiency results in cardiac dysfunction by compromising both Z-disc- and intercalated disc-mediated mechanotransduction","date":"2025-10-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.03.680335","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.09.658637","title":"The Desmoglein 2 interactome in primary neonatal cardiomyocytes","date":"2025-06-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.09.658637","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.25.661311","title":"Autoantibodies in patients with arrhythmogenic cardiomyopathy activate GSK-3β resulting in a loss of cardiomyocyte cohesion","date":"2025-06-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.25.661311","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.23.643549","title":"Screening for pro-adhesive compounds and their relevance as therapeutic approach in Arrhythmogenic Cardiomyopathy","date":"2025-03-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.23.643549","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.11.628020","title":"Interleukin-1β Drives Disease Progression in Arrhythmogenic Cardiomyopathy","date":"2024-12-17","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.11.628020","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.29.25324867","title":"Genomic and molecular evidence that the lncRNA<i>DSP-AS1</i>modulates Desmoplakin expression","date":"2025-03-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.29.25324867","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.01.601522","title":"Dsg2 truncation causes a lethal barrier breakdown in mice","date":"2024-07-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.01.601522","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.17.649297","title":"Apremilast improves cardiomyocyte cohesion and arrhythmia in different models for arrhythmogenic cardiomyopathy","date":"2025-04-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.17.649297","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.12.08.24318665","title":"Genetic Causes of Sudden Cardiac Arrest in the Community","date":"2024-12-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.08.24318665","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.15.24310426","title":"The novel duodenal isolate<i>Streptococcus salivarius</i>AGIRA0003 promotes barrier dysfunction and IgG responses in functional dyspepsia","date":"2024-07-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.15.24310426","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.15.676363","title":"P-cadherin and desmoglein-2 interact as strand-swap dimers and facilitate desmosome assembly","date":"2025-09-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.15.676363","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48150,"output_tokens":7921,"usd":0.131633},"stage2":{"model":"claude-opus-4-6","input_tokens":11766,"output_tokens":3411,"usd":0.216158},"total_usd":0.347791,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"DSG2 was identified as the ubiquitous desmoglein isoform present in all desmosome-containing tissues (epithelia, myocardium, lymph node follicles), encoding a 1069 amino acid transmembrane glycoprotein that functions as a Ca2+-dependent cell adhesion molecule and component of the desmosomal cadherin complex.\",\n      \"method\": \"cDNA cloning, amino acid sequence analysis, Northern blot, tissue expression profiling\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning and characterization with comprehensive expression profiling across tissues; foundational paper with 216 citations\",\n      \"pmids\": [\"8143788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"DSG2 protein localizes to desmosomes in all desmosome-containing tissues including stratified and simple epithelia, myocardium, and lymph node follicles; in stratified squamous epithelia, DSG2 is restricted to the basal cell layer. Antibodies to extracellular domains react with half-desmosomes on surfaces of uncoupled epithelial cells, demonstrating its role in cell-cell coupling.\",\n      \"method\": \"Immunocytochemistry with monoclonal and polyclonal antibodies targeting extracellular and cytoplasmic domains\",\n      \"journal\": \"Differentiation; research in biological diversity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by multiple antibodies in multiple tissues, replicated across labs\",\n      \"pmids\": [\"8641550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The fourth armadillo repeat of plakoglobin is required for its high-affinity binding to the cytoplasmic domain of DSG2; bacterially expressed 12-repeat plakoglobin (lacking the fourth repeat) binds DSG2 with lower affinity than the 13-repeat form, establishing DSG2 as a direct binding partner of plakoglobin at desmosomes.\",\n      \"method\": \"In vitro binding assay with bacterially expressed proteins, deletion mutant analysis\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro binding with mutagenesis (deletion of specific armadillo repeat)\",\n      \"pmids\": [\"8749329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Suprabasal overexpression of DSG2 in transgenic mouse epidermis causes keratinocyte hyperproliferation, apoptosis resistance, and skin tumor susceptibility through activation of multiple signaling pathways including PI3K/AKT, MEK-MAPK, STAT3, and NF-κB, with enhanced EGF receptor activation required for anchorage-independent survival.\",\n      \"method\": \"Transgenic mouse model (involucrin-promoter Dsg2), ex vivo keratinocyte culture, pathway inhibitor studies, chemical carcinogenesis assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function in vivo with multiple pathway readouts and pharmacological validation; 102 citations\",\n      \"pmids\": [\"17284515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The DSG2-N266S mutation acts in a dominant-negative, dose-dependent manner to cause arrhythmogenic right ventricular cardiomyopathy (ARVC) in transgenic mice; myocyte necrosis is the key initiating event, triggering inflammatory response, calcification, fibrous tissue replacement, and myocardial atrophy.\",\n      \"method\": \"Cardiac-specific transgenic mouse overexpressing mutant dsg2 (N271S), multiple transgene expression levels, histopathology, electrophysiology\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dose-dependent dominant-negative effect shown across multiple transgenic lines with mechanistic histopathological analysis; 167 citations\",\n      \"pmids\": [\"19635863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DSG2 activates EGFR signaling through a c-Src and Caveolin-1 (Cav1)-dependent mechanism via lipid rafts: DSG2 overexpression recruits to and displaces Cav1, EGFR, and c-Src from light-density lipid raft fractions, leading to c-Src and EGFR activation, increased cell proliferation and migration. DSG2 knockdown abrogates EGFR, c-Src, and STAT3 activation in response to EGF.\",\n      \"method\": \"Sucrose density fractionation, STED imaging, siRNA knockdown, overexpression in SCC cells, proliferation and migration assays, lipid raft perturbation (MβCD)\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (fractionation, super-resolution imaging, KD/OE, pharmacological perturbation) in single study\",\n      \"pmids\": [\"26918609\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ARVC-associated DSG2 mutations (studied by single-molecule force spectroscopy) significantly alter the kinetics and thermodynamics of homophilic DSG2 dimerization without directly affecting the binding motif; the free energy landscape of DSG2 dimerization reveals a high activation barrier consistent with a strand-swapping binding motif, and mutations reduce cell-cell adhesion in a dispase-based assay.\",\n      \"method\": \"Single-molecule force spectroscopy, Jarzynski's equality for thermodynamic analysis, dispase-based cell dissociation assay with HT1080 cells overexpressing WT and mutant Dsg2\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — single-molecule biophysics combined with cellular adhesion assay; rigorous thermodynamic characterization of binding mechanism\",\n      \"pmids\": [\"29062102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DSG2 directly interacts with EGFR and undergoes heterotypic binding events on the surface of living enterocytes via its extracellular domain; DSG2 is required for EGFR localization at intercellular junctions and for Src-mediated EGFR activation; Src binds EGFR and is required for co-localization of EGFR and DSG2 at cell-cell contacts. DSG2-deficient enterocytes show impaired barrier properties and increased proliferation.\",\n      \"method\": \"Atomic force microscopy on living cells, Co-IP, siRNA knockdown, EGFR localization imaging, barrier function assays\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding shown by AFM on live cells plus Co-IP; loss-of-function with defined cellular phenotype\",\n      \"pmids\": [\"29980799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DSG2 regulates self-renewal and pluripotency of human pluripotent stem cells predominantly through β-catenin/Slug-mediated epithelial-to-mesenchymal transition (EMT); DSG2 depletion markedly decreased hPSC proliferation, pluripotency marker expression, and embryonic body and teratoma formation.\",\n      \"method\": \"Monoclonal antibody-based identification, siRNA knockdown, flow cytometry, embryoid body and teratoma assays, Western blot for β-catenin/Slug pathway\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular pathway (β-catenin/Slug/EMT) but mechanistic link relies on downstream pathway analysis without direct DSG2-β-catenin interaction assay\",\n      \"pmids\": [\"29910125\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ARVC-associated DSG2 mutations alter the N-glycosylation pattern of desmoglein-2; wildtype and mutant DSG2 display different glycosylation patterns despite mutations not directly affecting N-glycosylation consensus sequences, indicating complex molecular interactions between DSG2 mutations and N-glycosylations.\",\n      \"method\": \"De-glycosylation assays, lectin blot analysis, genetic inhibition of glycosylation\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal biochemical methods in single study; single lab\",\n      \"pmids\": [\"30885746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DSG2 undergoes heterophilic interactions with DSG3; immunoprecipitation and cell-free atomic force microscopy demonstrated Dsg2-Dsg3 heterophilic binding with comparable frequency, strength, Ca2+-dependency, and catch-bond behavior to homophilic interactions, but with longer lifetime. Heterophilic Dsg2-Dsg3 interactions are significantly less inhibited by pemphigus vulgaris autoantibodies compared to homophilic Dsg3 interactions.\",\n      \"method\": \"Co-immunoprecipitation, cell-free atomic force microscopy, Dsg3-deficient keratinocyte model, pemphigus skin ex vivo model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — cell-free AFM plus Co-IP provides direct biophysical and biochemical evidence of heterophilic interaction with functional consequence\",\n      \"pmids\": [\"33193387\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DSG2 knockdown in anaplastic thyroid cancer cells increased cell migration and invasion through the c-Met/Src/Rac1 signaling axis without altering EMT markers; specific c-Met inhibition blocked motility of shDsg2-depleted cells, and decreased membrane DSG2 increased metastatic potential in vivo.\",\n      \"method\": \"shRNA knockdown, migration/invasion assays, in vivo metastasis model, pharmacological c-Met inhibition, Western blot for signaling intermediates\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined pathway placement (c-Met/Src/Rac1) and in vivo validation\",\n      \"pmids\": [\"33022637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A DSG2 truncation mutation (p.S363X) localized in the extracellular domain results in absence of the truncated protein at the plasma membrane, as shown by in vitro transfection experiments, supporting loss-of-function through failure of membrane trafficking.\",\n      \"method\": \"In vitro cell transfection, immunofluorescence localization of truncated vs. wildtype DSG2\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment with functional implication; single lab, single method\",\n      \"pmids\": [\"34202524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Cardiac-specific knockout of Dsg2 causes myocardial lipid accumulation and cardiac dysfunction through impaired fatty acid β-oxidation resulting from declined mTOR-4EBP1-PPARα signaling; rapamycin worsened while mTOR/4EBP1 overexpression or PPARα reactivation (fenofibrate/AAV9-Pparα) rescued the phenotype.\",\n      \"method\": \"Cardiac-specific Dsg2 knockout mouse, echocardiography, lipid staining, Western blot, AAV-mediated gene delivery, rapamycin treatment, pharmacological PPARα activation\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cardiac-specific KO with multiple orthogonal rescue experiments defining the mTOR-4EBP1-PPARα pathway\",\n      \"pmids\": [\"36815030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Dsg2 deficiency causes cardiac fibrosis via PPARα deficiency and hyperactivation of STAT3 and SMAD3; Dsg2 gene silencing in HL-1 cells upregulates fibrotic markers (α-SMA, Collagen I); STAT3 siRNA inhibits fibrotic marker expression; PPARα activation by fenofibrate or AAV9-Pparα reduces fibrosis and decreases phosphorylation of STAT3, SMAD3, and AKT.\",\n      \"method\": \"CS-Dsg2-/- mouse, Masson staining, Western blot, qPCR, siRNA knockdown in HL-1 cells, AAV gene delivery\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO model with siRNA epistasis and multiple rescue experiments defining PPARα-STAT3-SMAD3 pathway\",\n      \"pmids\": [\"36291052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TROP2 interacts with DSG2 in gastric cancer cells (identified by co-immunoprecipitation and mass spectrometry); TROP2 overexpression reduces DSG2 levels and desmosome adhesion, promoting cell invasion and migration through EGFR/AKT and DSG2/plakoglobin/β-catenin pathways.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, TROP2 overexpression/knockdown, electron microscopy of desmosome assembly, Western blot for pathway analysis\",\n      \"journal\": \"Current cancer drug targets\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP/MS for interaction plus functional pathway analysis; single lab\",\n      \"pmids\": [\"35392784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRKD2 (serine/threonine-protein kinase D2) phosphorylates DSG2 at threonine 730 (T730); this phosphorylation promotes esophageal squamous cell carcinoma cell migration and invasion by activating EGFR, Src, AKT, and ERK signaling pathways; DSG2-T730 phosphorylation-deficient mutants abolish the pro-migratory effect.\",\n      \"method\": \"Interactome analysis, phosphorylation assay, site-directed mutagenesis (T730), migration/invasion assays, Western blot for signaling pathways\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — identification of kinase-substrate relationship with mutagenesis of phosphorylation site and functional validation\",\n      \"pmids\": [\"38411280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DSG2 F531C mutation causes protein misfolding recognized by BiP within the endoplasmic reticulum, triggering ER stress and activating PERK-ATF4 signaling; elevated ATF4 increases TGF-β1 expression in cardiomyocytes, which activates cardiac fibroblasts via paracrine signaling to promote cardiac fibrosis; PERK-ATF4 inhibition attenuated fibrosis in knock-in mice.\",\n      \"method\": \"Dsg2 F536C knock-in mice (CRISPR/Cas9), transcriptomic analysis, mass spectrometry, Co-IP with BiP, neonatal/adult cardiomyocytes isolation, PERK inhibitor treatment, histopathology\",\n      \"journal\": \"BMC medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — knock-in model with mechanistic pathway dissection using Co-IP, transcriptomics, MS, and pharmacological rescue\",\n      \"pmids\": [\"39227800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DSG2 ectodomain organization (measured by fluorescence polarization) gradually increases over 8 hours during desmosome assembly and correlates with increasing adhesive strength; in wound healing, ectodomain order increases in assembling desmosomes at the leading edge of migratory cells.\",\n      \"method\": \"Fluorescence polarization microscopy, scratch wound assay, time-lapse imaging\",\n      \"journal\": \"Cell adhesion & migration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct structural measurement during assembly with functional correlation; single lab\",\n      \"pmids\": [\"38566311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DSG2 is identified as a dominant counter receptor of Siglec-9 in melanoma cells via proximity labeling and CRISPR knockout screening; the DSG2-Siglec-9 interaction is mainly dependent on sialic acid-bearing N-glycans on DSG2; blocking this interaction significantly enhances macrophage phagocytosis of melanoma cells.\",\n      \"method\": \"Proximity labeling, CRISPR knockout screening, binding assays, macrophage phagocytosis assay, glycan dependency analysis\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal discovery methods (proximity labeling + CRISPR screen) with mechanistic follow-up showing glycan dependency and functional phagocytosis readout\",\n      \"pmids\": [\"39813162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"DSG2 interacts with c-MYC (by co-immunoprecipitation) in cervical cancer cells; DSG2 overexpression combined with c-MYC inhibition significantly decreases cell proliferation, migration, and ADAM17 expression compared to DSG2 overexpression alone, placing DSG2 upstream of c-MYC/ADAM17 in a proliferation/migration pathway.\",\n      \"method\": \"Co-immunoprecipitation, c-MYC inhibitor treatment, qPCR, Western blot, CCK-8 and Transwell assays\",\n      \"journal\": \"Cancer management and research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP for interaction with functional epistasis; single lab\",\n      \"pmids\": [\"38948682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DSG2 deficiency in cardiomyocytes results in Z-disc structural defects and increased myosin detachment rate; Ca2+-activated force is markedly reduced in DSG2-mutant permeabilized left ventricular cardiac muscle bundles but preserved in isolated permeabilized cardiomyocytes, revealing that DSG2 is required for force transmission between sarcomeres (tissue-level mechanotransduction) in addition to cell-cell mechanical coupling.\",\n      \"method\": \"Homozygous Dsg2 knock-in mice (adolescent and adult), permeabilized cardiac muscle bundles vs. isolated cardiomyocyte force measurements, X-ray diffraction, echocardiography\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — rigorous mechanical measurements distinguishing tissue vs. cell levels; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.10.03.680335\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Proximity labeling and quantitative mass spectrometry identified over 300 proteins in the DSG2 interactome in neonatal cardiomyocytes; unique DSG2-associated proteins include connexin 43 (gap junction protein) and plakin family cytolinker proteins; plakoglobin (JUP) and plakophilin 2 (PKP2) are the most abundant proteins shared between DSG2 and N-cadherin interactomes.\",\n      \"method\": \"Proximity labeling (BioID), quantitative mass spectrometry, comparison with N-cadherin interactome\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic proximity labeling MS identifies interactome; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.06.09.658637\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"P-cadherin (Pcad) facilitates desmosome assembly by directly interacting with DSG2 on opposing cells via heterophilic strand-swap dimerization involving conserved tryptophan residues; stiffening the hinge on the swapped β-strands reduces heterophilic dimer formation; introduction of strand-swap competent Pcad into cells lacking classical cadherins rescues desmosome assembly.\",\n      \"method\": \"Single-molecule atomic force microscopy, super-resolution and confocal imaging, site-directed mutagenesis of strand-swap residues, atomistic simulations, cell-based desmosome assembly assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — single-molecule biophysics plus mutagenesis plus cell rescue assay; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.09.15.676363\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Pathogenic autoantibodies from ACM patients bind DSG2 in hiPSC-CMs, cleave DSG2, and reduce DSG2 interaction at the molecular level; these autoantibodies impair cardiomyocyte cohesion by activating GSK-3β upstream of p38MAPK, leading to phosphorylation and junctional loss of β-catenin; GSK-3β inhibition rescues the loss of cell cohesion induced by ACM autoantibodies.\",\n      \"method\": \"hiPSC-cardiomyocytes from ACM patients, IgG fractionation, dispase dissociation assay, GSK-3β inhibition, Western blot for p38MAPK/β-catenin phosphorylation\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway dissection with pharmacological rescue; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.06.25.661311\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Oxymatrine (OMT) directly binds DSG2 (confirmed by CETSA, DARTS, and microscale thermophoresis) and stabilizes it; OMT and its metabolite matrine reduce DSG2 cleavage by inhibiting caspase-8 activity, thereby enhancing intestinal epithelial barrier function; knockdown of DSG2 abolishes the protective effects of OMT.\",\n      \"method\": \"CETSA, DARTS, microscale thermophoresis, caspase-8 activity assay, lentiviral DSG2 knockdown, Caco-2 and FD duodenal spheroid models\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — three orthogonal direct binding methods plus mechanistic follow-up showing caspase-8 cleavage and KD rescue\",\n      \"pmids\": [\"41076918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"DSG2 mediates conversion between desmosome and adherens junctions in circulating tumor cell (CTC) clusters; high DSG2 expression maintains desmosome-dominant intercellular junctions in CTC clusters; HIF-1α positively controls DSG2-mediated desmosome junctions; inhibiting HIF-1α promotes conversion from desmosome to adherens junctions, destabilizing CTC clusters.\",\n      \"method\": \"CTC cluster analysis, junction protein characterization by IF, HIF-1α inhibition, in vivo metastasis models\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined pathway (HIF-1α→DSG2→desmosome junction type) and in vivo validation; single lab\",\n      \"pmids\": [\"41381723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ectopic suprabasal expression of DSG2 in transgenic mice reduces epidermal blister formation in response to pemphigus foliaceus antibodies and exfoliative toxins (ETA); DSG2 overexpression enhances retention of DSG1 at cell-cell borders, demonstrating DSG2's direct role in cell adhesion and protection of desmosomal components.\",\n      \"method\": \"Transgenic mouse model (involucrin-Dsg2), injection of ETA and PF IgG, immunofluorescence for Dsg1 localization\",\n      \"journal\": \"Dermatology research and practice\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function transgenic model with defined adhesion phenotype; single lab\",\n      \"pmids\": [\"20631906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"UV radiation induces DSG2 downregulation in human lens epithelial cells via EGFR activation, Rac2 translocation, and NADPH oxidase-mediated generation of reactive oxygen species (ROS); this pathway is analogous to that activated by H2O2 treatment.\",\n      \"method\": \"Cell culture, UV irradiation, ROS measurement, EGFR activation assay, Rac2/NADPH oxidase activity, Western blot for DSG2\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined molecular pathway (EGFR→Rac2/NADPH oxidase→ROS→DSG2 downregulation) with pharmacological/genetic dissection; single lab\",\n      \"pmids\": [\"16820949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"DSG2 regulates cystatin A (CSTA) expression in keratinocytes; knockdown of DSG2 reduces CSTA expression; conversely, CSTA knockdown causes cytoplasmic mislocalization of DSG2, perturbs cytokeratin 14, reduces desmoplakin levels, and induces loss of cell adhesion. Combined knockdown of DSG2 and CSTA has a synergistic effect on loss of adhesion, demonstrating crosstalk between DSG2 and CSTA in regulating cell-cell adhesion.\",\n      \"method\": \"siRNA/shRNA knockdown, microarray, qPCR, immunoblotting, immunohistochemistry, dispase-based adhesion assay, mechanical stretching\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal knockdown experiments with defined adhesion phenotype and localization readout; single lab\",\n      \"pmids\": [\"25785582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DSG2 overexpression in basal keratinocytes accelerates full-thickness wound closure and increases wound-adjacent keratinocyte proliferation; DSG2 induces increased release and proteolytic processing of urokinase-type plasminogen activator receptor (uPAR), and wounding further enhances uPAR and laminin-332 in transgenic epidermis.\",\n      \"method\": \"Transgenic mice (keratin14-Dsg2), wound healing assay, antibody profiler secretome array, immunohistochemistry\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with defined wound healing phenotype and secretome analysis linking mechanism to uPAR; single lab\",\n      \"pmids\": [\"29753032\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DSG2 is a transmembrane desmosomal cadherin that mediates Ca2+-dependent homophilic and heterophilic (DSG3, P-cadherin) cell-cell adhesion via strand-swap dimerization of its extracellular domain; intracellularly it binds plakoglobin (requiring the fourth armadillo repeat) and associates with connexin 43 and plakin cytolinkers in cardiomyocytes; at the plasma membrane DSG2 organizes lipid raft signaling platforms to activate EGFR via c-Src/Cav1-dependent transactivation, stimulating PI3K/AKT, MEK-MAPK, STAT3, and NF-κB pathways that drive proliferation, survival, and migration; PRKD2 phosphorylates DSG2 at T730 to further potentiate EGFR/Src/AKT/ERK signaling; in cardiomyocytes, DSG2 loss disrupts intercalated disc integrity, impairs force transmission between sarcomeres, and through ER stress-PERK-ATF4-TGF-β1 and mTOR-PPARα axes drives the fibrofatty remodeling characteristic of arrhythmogenic cardiomyopathy; sialylated N-glycans on DSG2 enable it to act as a 'don't eat me' signal by engaging Siglec-9 on macrophages, and the extracellular domain serves as a functional receptor for group B human adenoviruses.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"DSG2 is a ubiquitously expressed desmosomal cadherin that mediates Ca²⁺-dependent cell-cell adhesion through homophilic and heterophilic strand-swap dimerization and couples intercellular junctions to intracellular signaling networks controlling proliferation, survival, and tissue integrity. Its extracellular domain engages in homophilic binding with high activation-barrier kinetics consistent with strand-swapping, forms heterophilic dimers with DSG3 and P-cadherin, and carries sialylated N-glycans that engage macrophage Siglec-9 to suppress phagocytosis [PMID:29062102, PMID:33193387, PMID:39813162]. Intracellularly, DSG2 binds plakoglobin (via armadillo repeat 4), organizes lipid raft signaling platforms to activate EGFR through c-Src/Caveolin-1-dependent transactivation driving PI3K/AKT, MEK-MAPK, STAT3, and NF-κB cascades, and is phosphorylated by PRKD2 at T730 to potentiate EGFR/Src/AKT/ERK signaling [PMID:8749329, PMID:26918609, PMID:38411280]. Loss-of-function and dominant-negative DSG2 mutations cause arrhythmogenic cardiomyopathy through myocyte necrosis, ER stress–PERK–ATF4–TGF-β1-driven fibrosis, and impaired mTOR–PPARα-dependent fatty acid oxidation, establishing DSG2 as a causal gene for this disease [PMID:19635863, PMID:39227800, PMID:36815030].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing DSG2 as the ubiquitous desmosomal cadherin resolved the question of which desmoglein isoform is present across all desmosome-bearing tissues, providing the foundation for all subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning, sequence analysis, and Northern blot across multiple tissues\",\n      \"pmids\": [\"8143788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No functional assay of adhesion performed\", \"Protein-level expression not quantified across tissues\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Demonstration that DSG2 localizes to desmosomes and half-desmosomes on uncoupled cell surfaces established its direct participation in cell-cell coupling rather than merely being a desmosome-associated protein.\",\n      \"evidence\": \"Immunocytochemistry with multiple antibodies in stratified/simple epithelia and myocardium\",\n      \"pmids\": [\"8641550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No dynamic assembly or turnover measurement\", \"Localization in non-epithelial cell types incompletely mapped\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of the plakoglobin–DSG2 interaction via armadillo repeat 4 defined the first direct cytoplasmic binding partner, explaining how DSG2 couples to the desmosomal plaque.\",\n      \"evidence\": \"In vitro binding assay with bacterially expressed deletion mutants of plakoglobin\",\n      \"pmids\": [\"8749329\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo validation of armadillo repeat 4 requirement\", \"Other cytoplasmic partners not addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Transgenic DSG2 overexpression in mouse epidermis revealed that DSG2 is not merely a structural adhesion molecule but an activator of PI3K/AKT, MEK-MAPK, STAT3, and NF-κB signaling via EGFR, explaining how desmosomal cadherins influence proliferation and tumor susceptibility.\",\n      \"evidence\": \"Involucrin-Dsg2 transgenic mice with pathway inhibitor studies and chemical carcinogenesis\",\n      \"pmids\": [\"17284515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct DSG2–EGFR interaction mechanism not resolved\", \"Signaling model based on overexpression, not endogenous levels\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The Dsg2-N266S transgenic mouse demonstrated that ARVC-associated DSG2 mutations act in a dominant-negative manner, with myocyte necrosis as the initiating event preceding fibrofatty replacement — establishing the disease mechanism in vivo.\",\n      \"evidence\": \"Cardiac-specific transgenic mouse with graded expression levels, histopathology, electrophysiology\",\n      \"pmids\": [\"19635863\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether necrosis versus apoptosis predominates remained debated\", \"Downstream molecular pathways from DSG2 loss to necrosis not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Mechanistic dissection of DSG2-EGFR crosstalk showed that DSG2 organizes lipid raft platforms and displaces Caveolin-1, enabling c-Src-dependent EGFR transactivation — explaining the signaling effects observed in transgenic mice.\",\n      \"evidence\": \"Sucrose density fractionation, STED imaging, siRNA knockdown, MβCD perturbation in SCC cells\",\n      \"pmids\": [\"26918609\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical DSG2–EGFR binding not demonstrated at this stage\", \"Mechanism of Cav1 displacement unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Single-molecule force spectroscopy revealed that DSG2 homophilic dimerization follows strand-swap mechanics with a high activation barrier, and that ARVC mutations alter binding kinetics without disrupting the binding motif — providing a biophysical explanation for how mutations weaken adhesion.\",\n      \"evidence\": \"Single-molecule AFM force spectroscopy with Jarzynski analysis plus dispase assay in HT1080 cells\",\n      \"pmids\": [\"29062102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of kinetic changes not resolved at atomic level\", \"In vivo relevance of altered kinetics not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Direct DSG2–EGFR interaction on living enterocyte surfaces was confirmed by AFM, and DSG2 was shown to be required for EGFR junctional localization via Src, closing the gap between lipid raft models and direct receptor engagement.\",\n      \"evidence\": \"AFM on living cells, Co-IP, siRNA knockdown in enterocytes with barrier function readout\",\n      \"pmids\": [\"29980799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface between DSG2 and EGFR ectodomains not mapped\", \"Whether interaction is direct or adaptor-mediated at atomic resolution unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery of heterophilic DSG2–DSG3 binding with catch-bond behavior and longer lifetime than homophilic interactions expanded the adhesion model beyond homodimerization and explained partial resistance to pemphigus autoantibodies.\",\n      \"evidence\": \"Cell-free AFM and Co-IP with Dsg3-deficient keratinocytes and pemphigus skin ex vivo model\",\n      \"pmids\": [\"33193387\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of heterophilic versus homophilic preference not determined\", \"In vivo significance of heterophilic binding in intact desmosomes not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cardiac-specific Dsg2 knockout revealed that DSG2 loss causes lipid accumulation and cardiac dysfunction through impaired mTOR–4EBP1–PPARα signaling and parallel STAT3/SMAD3-driven fibrosis, providing the first metabolic explanation for arrhythmogenic cardiomyopathy pathogenesis downstream of desmosome disruption.\",\n      \"evidence\": \"Cardiac-specific Dsg2 KO mice with rapamycin worsening, AAV-PPARα rescue, fenofibrate treatment, siRNA epistasis in HL-1 cells\",\n      \"pmids\": [\"36815030\", \"36291052\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DSG2 loss signals to mTOR not defined\", \"Whether metabolic dysfunction is primary or secondary to structural defects unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of PRKD2 as the kinase phosphorylating DSG2 at T730 established the first site-specific post-translational modification that potentiates DSG2-EGFR/Src/AKT/ERK signaling, linking kinase signaling directly to desmosomal cadherin function in cancer cell migration.\",\n      \"evidence\": \"Interactome analysis, phosphorylation assay, T730A mutagenesis, migration/invasion assays in ESCC cells\",\n      \"pmids\": [\"38411280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether T730 phosphorylation occurs in normal tissues unknown\", \"Phosphatase responsible for dephosphorylation not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The Dsg2-F531C knock-in mouse showed that ARVC mutations can trigger ER stress through BiP recognition of misfolded DSG2, activating PERK–ATF4–TGF-β1 paracrine signaling from cardiomyocytes to fibroblasts — providing a proteostasis-based fibrosis mechanism distinct from the mTOR/PPARα axis.\",\n      \"evidence\": \"CRISPR knock-in mice, Co-IP with BiP, transcriptomics, MS, PERK inhibitor rescue\",\n      \"pmids\": [\"39227800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ER stress pathway is universal across all ARVC-associated DSG2 mutations not tested\", \"Relative contribution of ER stress versus metabolic pathways to disease unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of DSG2 as the dominant Siglec-9 counter-receptor on melanoma cells, dependent on sialylated N-glycans, revealed a glyco-immune checkpoint function for DSG2 as a 'don't eat me' signal — expanding its role beyond adhesion into immune evasion.\",\n      \"evidence\": \"Proximity labeling, CRISPR KO screening, glycan dependency analysis, macrophage phagocytosis assay\",\n      \"pmids\": [\"39813162\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether DSG2–Siglec-9 interaction occurs in non-melanoma contexts unknown\", \"In vivo therapeutic significance of blocking this axis not yet established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution structure of DSG2 in complex with EGFR and Siglec-9, the mechanism by which DSG2 loss activates mTOR suppression in cardiomyocytes, and whether the ER stress and metabolic pathways represent parallel or convergent disease mechanisms in arrhythmogenic cardiomyopathy.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal/cryo-EM structure of DSG2 ectodomain complexes with non-cadherin partners\", \"Mechanism linking DSG2 loss to mTOR inactivation undefined\", \"Relative contributions of ER stress versus metabolic versus mechanical defects to ARVC progression unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1, 6, 10, 23]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 5, 7, 12]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 7, 16]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 6, 10, 27]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 13, 14, 17]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"complexes\": [\n      \"desmosome\",\n      \"intercalated disc\"\n    ],\n    \"partners\": [\n      \"JUP\",\n      \"EGFR\",\n      \"DSG3\",\n      \"PKP2\",\n      \"PRKD2\",\n      \"GJA1\",\n      \"TROP2\",\n      \"SIGLEC9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}